Intrapulmonary pharmacokinetics of telithromycin, a new ketolide, in healthy Japanese volunteers

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 3, 2002, Pages 917-921

  Kadota, Jun Ichi ^a   Ishimatsu, Yuji ^a   Iwashita, Tetsuji ^a   Matsubara, Yuichi ^a   Tomono, Kazunori ^a   Tateno, Masao ^a   Ishihara, Roza ^a   Muller Serieys, Claudette ^a   Kohno, Shigeru ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

KETOLIDE; TELITHROMYCIN;

ADULT; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATION; CLINICAL ARTICLE; DRUG EFFECT; DRUG PENETRATION; HUMAN; LUNG ALVEOLUS MACROPHAGE; LUNG FUNCTION TEST; LUNG LAVAGE; LUNG PARENCHYMA; MACROPHAGE ACTIVATION; MALE; PRIORITY JOURNAL; SPIROMETRY; TISSUE DISTRIBUTION;

ADULT; ANTI-BACTERIAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; HUMANS; KETOLIDES; LUNG; MACROLIDES; MALE; PROSPECTIVE STUDIES;

EID: 0036168517     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.3.917-921.2002     Document Type: Article

References (21)

1. Sporicidal activity of local anaesthetics and their binary combinations with preservatives
2. In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae
3. In vitro activity of ketolides against mycoplasmas
4. Interpretation of pharmacologic data in respiratory tract infections
5. Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains
6. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin
7. Cell numbers and cell characteristics of the normal human lung
8. Synthesis and antibacterial activity of HMR 3647, a new ketolide highly potent against erythromycin-resistant and susceptible pathogens
9. Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: Focus on telithromycin
10. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia
11. Practical considerations and guidelines for the management of community-acquired pneumonia
12. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis
13. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. surveillance study
14. Lung concentrations of telithromycin after oral dosing
15. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents
16. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin
17. Ketolide treatment of Haemophilus influenzae experimental pneumonia
18. Estimation of volume of epithelial lining fluid recovered by lavage using urea as a marker of dilution
19. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae
20. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998
21. Susceptibilities of Legionella spp. to newer antimicrobials in vitro